Verisk Says It Will Follow Delaware Court Order To Pursue $2.35 Billion AccuLynx Deal

Delaware's Supreme Court affirmed a ruling against Verisk's exit, and the company says closing is not guaranteed with FTC review pending.

Share
Verisk Says It Will Follow Delaware Court Order To Pursue $2.35 Billion AccuLynx Deal

Verisk Analytics, which sells data, analytics and software to insurers, said in an 8-K filed Thursday that it will comply with a Delaware Supreme Court order affirming the ruling that blocked its attempt to walk away from the $2.35 billion AccuLynx acquisition. The company warned that FTC review is still pending and that completion is not assured.

Verisk's response to the court

The court order came October 23, and Verisk issued a statement that day saying it respects the decision to affirm the Delaware Chancery Court's judgment. "We will proceed in accordance with the Court's order," the company said.

Verisk added that the deal remains subject to customary closing conditions and FTC review, and that "there is no guarantee that the transaction will be completed."

The affirmed ruling leaves Verisk obligated to keep seeking antitrust clearance for the deal and to close if regulators approve, Law360 reported. The Chancery Court had also approved $3.85 million in damages for AccuLynx and ordered specific performance, meaning Verisk must carry out the contract.

How the exit attempt unraveled

Verisk announced the AccuLynx purchase in July 2025. It tried to terminate in December, after the FTC said its review would not finish by the December 26 termination date, according to Insurance Journal. AccuLynx argued Verisk itself caused that delay.

In August, Chancery Court Judge Bonnie David found the termination invalid because Verisk's own willful conduct caused a closing condition to fail.

The business behind the deal

Verisk's tools help insurers price risk, handle claims, detect fraud and model catastrophes such as hurricanes and wildfires. It also sells software to the specialty insurance market. Subscriptions and long-term agreements made up over 80% of its 2025 revenues, according to its annual report.

The next decisive step is the FTC's review of the AccuLynx transaction; if regulators clear it, Verisk's obligation to close takes effect.

Sources